BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors. Clin Exp Gastroenterol 2020;13:131-9. [PMID: 32440190 DOI: 10.2147/CEG.S208020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Parigi SM, Larsson L, Das S, Ramirez Flores RO, Frede A, Tripathi KP, Diaz OE, Selin K, Morales RA, Luo X, Monasterio G, Engblom C, Gagliani N, Saez-Rodriguez J, Lundeberg J, Villablanca EJ. The spatial transcriptomic landscape of the healing mouse intestine following damage. Nat Commun 2022;13:828. [PMID: 35149721 DOI: 10.1038/s41467-022-28497-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Zhu M, Ran Z. Clinical characteristics of ulcerative colitis in elderly patients. JGH Open 2021;5:849-54. [PMID: 34386591 DOI: 10.1002/jgh3.12612] [Reference Citation Analysis]
3 Guo D, Jiang K, Hong J, Zhang M, Shi Y, Zhou B. Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis. Int J Colorectal Dis 2021;36:2081-92. [PMID: 34467414 DOI: 10.1007/s00384-021-04017-2] [Reference Citation Analysis]
4 Toskas A, Akbar A. IBD therapeutics: what is in the pipeline? Frontline Gastroenterol 2022;13:e35-43. [DOI: 10.1136/flgastro-2022-102130] [Reference Citation Analysis]
5 Kofla-Dłubacz A, Akutko K, Krzesiek E, Jamer T, Braksator J, Grębska P, Pytrus T, Stawarski A. Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases. J Clin Med 2022;11:994. [PMID: 35207271 DOI: 10.3390/jcm11040994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021;14:17562848211059954. [PMID: 34917173 DOI: 10.1177/17562848211059954] [Reference Citation Analysis]
7 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Li Y, Chen J, Bolinger AA, Chen H, Liu Z, Cong Y, Brasier AR, Pinchuk IV, Tian B, Zhou J. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S38-62. [PMID: 34791293 DOI: 10.1093/ibd/izab190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]